Amgen: Appeals Court Affirms Enbrel Patent Validity in Sandoz Dispute
July 01 2020 - 12:47PM
Dow Jones News
By Colin Kellaher
Amgen Inc. on Wednesday said a federal appeals court has upheld
the validity of two patents related to Enbrel, turning away a
challenge from a unit of Novartis AG that had hoped to launch a
biosimilar to the blockbuster rheumatoid-arthritis drug.
Amgen said the U.S. Court of Appeals for the Federal Circuit
affirmed a lower court ruling that upheld the validity of the
patents and resulted in an injunction prohibiting Novartis's Sandoz
unit from launching an Enbrel biosimilar.
That injunction stands, Amgen said Wednesday.
Biosimilars are near-copies of biologic drugs, such as Enbrel,
that are made from living cells and are analogous to generic copies
of traditional pill-form medicines.
The Thousand Oaks, Calif., biotechnology company had sued
Sandoz, claiming its biosimilar infringed on certain Enbrel
patents, while Sandoz had argued that the patents were invalid.
Shares of Amgen were recently up 6% to $250.07 after hitting a
52-week high of $250.25 earlier in the session.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 01, 2020 12:32 ET (16:32 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
